We were expecting the two components, the cells and the microenvironment, to evolve in lockstep. They did not,” said co-senior study author Marina Pasca di Magliano, Ph.D., Maud T. Lane Professor of Surgical Immunology and co-director of the Rogel and Blondy Center for Pancreatic Cancer at the University of Michigan.
A research team led by Fanyuan Yu from Sichuan University, China, has now discovered one of the mechanisms of DPSC senescence and identified a potential strategy to counter it.
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.
Researchers have identified a key protein that may help failing hearts regain function, offering new insight into why some hearts recover while others do not.
The study, conducted by researchers at Baylor College of Medicine and Texas Children’s Hospital, appeared in the American Journal of Human Genetics.
In the study, a multi-disciplinary research team led by Wyss Institute at Harvard University Founding Director Donald Ingber, M.D., Ph.D., worked with clinicians at McGill University in Canada and Massachusetts General Hospital who provided IBD and healthy tissue biopsies from the colon region of the same patients to create donor-specific microfluidic organ-on-a-chip (Organ Chip) models of colon that replicate major hallmarks of IBD in vitro in an unprecedented way.
A research team led by Professor Klaus Gerwert from Ruhr University Bochum, Germany, has developed just such a blood test. It is based on the immuno-infrared sensor, a novel platform technology to which the Journal of Physical Chemistry B dedicates its cover story in its issue from April 24, 2026.
FDA Registration Accelerates Healium Clinical’s Expansion into Healthcare Settings Nationwide
The approval is expected to drive increased clinical adoption and support applications for regulatory approval in other markets.
In a new study, Mass General Brigham investigators showed that patients with low-risk pancreatic cystic lesions (PCLs) have approximately 14 times higher risk of developing pancreatic cancer than the general population.